Market Overview

Benzinga's Top Upgrades

Share:
Benzinga's Top Upgrades
Related ABT
Weed Vs. Opioids: Nontraditional And Traditional Biotech Take On Wall Street, But Who's Winning?
Global Market For Medical Implants To Hit Nearly $27 Billion In 5 Years
Related PCLN
Vacasa And Booking.com Launch Partnership To Offer Alternative Accommodations On The Platform
Priceline's Decline Finds Support In A Familiar Area
Stock Indexes Rise; Boeing, Chip Stocks Advance (Investor's Business Daily)

Analysts at Goldman Sachs upgraded Abbott Laboratories (NYSE: ABT) from “neutral” to “buy.” The target price for Abbott Laboratories has been raised from $38 to $44. Abbott's stock closed at $36.59 on Friday.

Deutsche Bank upgraded priceline.com (NASDAQ: PCLN) from “hold” to “buy.” The target price for priceline.com has been raised from $715 to $900. priceline.com's shares closed at $813.66 on Friday.

Analysts at Maxim Group upgraded J.C. Penney Company (NYSE: JCP) from “hold” to “buy.” The target price for J.C. Penney has been raised from $16.50 to $27. J.C. Penney's shares closed at $18.01 on Friday.

Morgan Stanley upgraded E-Commerce China Dangdang (NYSE: DANG) from “equal-weight” to “overweight.” The target price for E-Commerce China Dangdang has been raised from $5 to $6.50. E-Commerce China Dangdang's shares closed at $5.71 on Friday.

Latest Ratings for ABT

DateFirmActionFromTo
May 2017Goldman SachsInitiates Coverage OnNeutral
Mar 2017BMO CapitalDowngradesOutperformMarket Perform
Sep 2016JefferiesMaintainsBuy

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: top upgradesUpgrades Analyst Ratings

 

Related Articles (ABT + DANG)

View Comments and Join the Discussion!